title: Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis.
abstract: The central nervous system lesions of multiple sclerosis (MS) can be detected by magnetic resonance imaging (MRI) and the initial perivascular inflammatory component is distinguished by the presence of gadolinium enhancement. To assess the effect of systemic lymphocyte depletion on disease activity, seven patients with MS received a 10-day intravenous course of the humanised monoclonal antibody CAMPATH-1H (anti-CDw52). With some variations in the protocol, enhanced cerebral MR images were obtained monthly for 3-4 months before and at least 6 months after treatment. 28 enhancing areas were detected on the first series of 7 scans; 51 additional active lesions were identified on 18 scans before treatment; 15 were detected on 20 scans done over the next 3 months, but only 2 active lesions were seen on 23 scans during follow-up beyond 3 months. The difference in lesion incidence rate before and after treatment varied and the rate ratio was significantly reduced in only three patients. Collectively, in a "meta-analysis", the rate ratios were 0.15 [corrected] (95% CI 0.09-0.24) for all seven patients and 0.24 (0.14-0.42; p < 0.001) with exclusion of the patient whose scanning schedule differed. The effect of CAMPATH-1H on disease activity provides direct, but preliminary, evidence that disease activity in MS depends on the availability of circulating lymphocytes and can be prevented by lymphocyte depletion. It is too early to say anything about the clinical results of treatment with this agent.
authors.affiliation: University of Cambridge Neurology Unit, Addenbrooke's Hospital, UK.
authors.forename: T
authors.initials: T
authors.lastname: Moreau
authors.forename: J
authors.initials: J
authors.lastname: Thorpe
authors.forename: D
authors.initials: D
authors.lastname: Miller
authors.forename: I
authors.initials: I
authors.lastname: Moseley
authors.forename: G
authors.initials: G
authors.lastname: Hale
authors.forename: H
authors.initials: H
authors.lastname: Waldmann
authors.forename: D
authors.initials: D
authors.lastname: Clayton
authors.forename: M
authors.initials: M
authors.lastname: Wing
authors.forename: N
authors.initials: N
authors.lastname: Scolding
authors.forename: A
authors.initials: A
authors.lastname: Compston
mesh_terms: D015703:Antigens, CD / Q000627:therapeutic use*; D000951:Antigens, Neoplasm; D001921:Brain / Q000473:pathology*; D000074301:CD52 Antigen; D003287:Contrast Media; D005260:Female; D005682:Gadolinium; D019786:Gadolinium DTPA; D006023:Glycoproteins; D006801:Humans; D008212:Lymphocyte Depletion; D008279:Magnetic Resonance Imaging; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology; D009942:Organometallic Compounds; D004369:Pentetic Acid / Q000031:analogs & derivatives
chemical_list: D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D003287:Contrast Media; D006023:Glycoproteins; D009942:Organometallic Compounds; D004369:Pentetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA